Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07284173

A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.

This clinical study is designed to evaluate a study medicine called PF-08049820. The main aim is to understand how the body processes this medicine and whether giving it with another medicine, rabeprazole, affects how it behaves.

The study will take in healthy adult participants aged 18 to 65 years who are not able to have children. Eligible participants must weigh more than 50 kilograms (110 pounds) and have a Body Mass Index (BMI) between 18.5 and 27.9.

Each participant will receive two treatments:

* One treatment with PF-08049820 alone * One treatment with PF-08049820 taken together with rabeprazole

Both medicines will be taken by mouth. Participants will stay at the study clinic for a few days during each treatment period. During these stays, the study team will collect blood samples to see how the body absorbs and processes the medicine.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Healthy Adults Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Skin Diseases Skin Diseases, Eczematous Skin Diseases, Genetic Skin and Connective Tissue Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Beijing Friendship Hospital Affiliate of Capital University, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female participants of non-childbearing potential aged 18 to 65 years, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12-lead electrocardiogram.
  • BMI of 18.5-27.9 kg/m2; and a total body weight >50 kg (110 lb).
  • Participants who are willing and able to comply with all scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

  • History or evidence of significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic diseases.
  • Positive test for HIV, hepatitis B (HBsAg), or hepatitis C (HCVAb).
  • Active or latent tuberculosis (TB) infection or inadequate treatment history for TB.
  • Any medical or psychiatric condition, including active suicidal ideation in the past year or suicidal behavior in the past 5 years, that may increase risk or interfere with study participation.
  • Current use of prohibited medications or inability/unwillingness to use required medications.

Treatment and study plan

PF-08049820

Drug

Oral tablets

rabeprazole

Drug

Oral tablets

Other names: Pariet

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of PF-08049820.

    Time frame: Day 1 through Day 38-45

  2. PK: Area under the plasma concentration (AUC) of PF-08049820

    Time frame: Day 1 through Day 38-45

Secondary outcomes

  1. Number of participants with treatment emergent adverse events

    Time frame: First dose through Day 38-45

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Phase 1, Open Label, Fixed Sequence Study to Investigate the Effect of Rabeprazole on the Pharmacokinetics of PF-08049820 in Healthy Chinese Adult Participants.

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 16, 2025
Registry last updated
Dec 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.